Nintedanib and Pembrolizumab

The combination of nintedanib and pembrolizumab represents a therapeutic approach that combines an anti-angiogenic tyrosine kinase inhibitor with an immune checkpoint inhibitor. Nintedanib is an oral multi-target tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors (VEGFR 1-3), platelet-derived growth factor receptors (PDGFR α and β), and fibroblast growth factor receptors (FGFR 1-3), as well as Src and Flt-3 kinases. This inhibition affects angiogenesis, fibrosis, and tumor growth by targeting multiple cellular processes. Pembrolizumab is a humanized monoclonal IgG4-kappa isotype antibody against programmed cell death protein 1 (PD-1) that blocks negative immune regulatory signaling, thereby enhancing T-cell mediated antitumor immune responses. The combination therapy leverages complementary mechanisms: 1. Nintedanib targets cancer-associated fibroblasts (CAFs) and attenuates the immunosuppressive tumor microenvironment. 2. This action promotes intratumoural accumulation and activation of CD8+ T cells. 3. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression on tumor cells, making them more responsive to immunotherapy. 4. The combination shows enhanced antitumor efficacy compared to either agent alone. This combination therapy shows promise for several cancer types, including non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, colorectal cancer, breast cancer, thymic carcinoma, cervical carcinoma, gastric adenocarcinoma, renal carcinoma, neuroendocrine tumors, and nasopharyngeal cancer. Additionally, nintedanib has shown potential for treating pembrolizumab-related pneumonitis, a serious immune-related adverse event, suggesting a dual benefit of the combination in both efficacy and safety.